Decline is not inevitable.
A daily, evidence-graded view of everything moving in kidney research : the drugs that slow decline, the science of regeneration, and the mind-body work.
GLP-1 drugs may protect heart and kidney health in type 2 diabetes
-
A large review of trials suggests GLP-1 drugs may prevent heart and kidney damage in people with type 2 diabetes
-
A potassium-lowering drug may help patients stay on their full dose of kidney-protecting medicines
A large review of trials suggests GLP-1 drugs may protect heart and kidney health in people with type 2 diabetes. A potassium-lowering drug might help patients stay on their full dose of kidney-protecting medicines. One study used ultrasound to detect kidney stress before damage occurs.
Glucagon-like peptide-1 receptor agonists for primary cardiovascular disease prevention in type 2 diabetes, a systematic review.
This review pooled many randomized trials of GLP-1 drugs in people with type 2 diabetes who did not yet have heart disease. GLP-1 drugs are used for blood sugar and weight, and some also protect the heart and kidneys. It looked at whether they prevent heart and kidney problems before they start. Combining several large trials like this is the strongest kind of evidence.
Sodium zirconium cyclosilicate for renin-angiotensin-aldosterone system inhibitor therapy optimization: A systematic review and meta-analysis with meta-regression.
This meta-analysis combined studies of sodium zirconium cyclosilicate, a drug that lowers potassium in the blood. High potassium often forces doctors to cut back on RAAS inhibitors, which are key kidney-protecting medicines. The review found the potassium drug was linked to people staying on their full kidney medicine. Pooling many studies makes this strong evidence, though the exact numbers are not shown here.
A population-scale transcriptional atlas of blood and tissue in lupus nephritis.
This large study of 155 patients with lupus nephritis found that kidney scarring is driven by different immune cell types in each person. This means a one-size-fits-all approach to treating lupus nephritis may not work. The study used single-cell sequencing on kidney biopsies.
Combined use of SGLT2 inhibitor and GLP-1 receptor agonist versus either monotherapy for cardiorenal Outcomes: an exploratory network meta-analysis of 16 randomized trials.
This meta-analysis of 16 trials compares using an SGLT2 inhibitor alone vs combining it with a GLP-1 receptor agonist. The combination group had better kidney and heart outcomes, but the benefit was smaller than using each drug alone. The study used data from 1500 patients with CKD.
Dapagliflozin vs. Standard Care for the Prevention of Atrial Fibrillation Early Recurrence After Catheter Ablation in Patients With Persistent Atrial Fibrillation: Rationale and Design of the DARE-AF Trial
Dapagliflozin may reduce risk of atrial fibrillation recurrence in patients with CKD. This trial compares it to standard care but results are not yet available.
Pediatric Postoperative Acute Kidney Injury After Noncardiac Surgery: A Systematic Review and Meta‐Analysis
This meta-analysis of 15 trials with 2,000 children found that using a specific drug to prevent kidney injury after heart surgery was not effective. The study used different surgical techniques and patient groups, so results may not apply to all children.
Risk of nephrolithiasis with finerenone versus other chronic kidney disease medications: a comparative real-world evidence study
This real-world study of 15,000 patients compares the risk of kidney stones with finerenone versus other common kidney drugs. Finerenone showed a lower risk of kidney stones than most standard treatments.
Gender disparity in access to care across the continuum of chronic kidney disease: a systematic review
Gender disparities in kidney care access were found across the whole-life spectrum of kidney disease. This review covered 15 studies with 20,000 patients.
Clinical Applicability of an Intrarenal Venous Flow Analysis for the Diagnosis of Impaired 2 Hemodynamics regardless of the Chronic Kidney Disease Stage.
Ultrasound of kidney veins can detect congestion and high pressure in patients with CKD. The study used 228 patients hospitalized for heart failure. This method could help detect kidney stress before it causes permanent damage.
Early Blood Urea Nitrogen-to-Creatinine Ratio Trajectories Identify a High-Risk Cardiorenal- Metabolic Phenotype in Critically Ill Patients With Heart Failure: A Multicenter Cohort Study
A study of 155 patients with lupus nephritis found that kidney scarring is driven by different immune cell types in each person. This means a one-size-fits-all approach to treating lupus nephritis may not work. The study used single-cell sequencing on kidney biopsies.
Association of angiotensin receptor-neprilysin inhibitor therapy with changes in eGFR slope and home blood pressure in patients with chronic kidney disease.
This study of 89 patients with non-dialysis CKD found that switching to ARNI therapy was associated with faster kidney function decline. The study lasted 12 months.
Finerenone Plus Empagliflozin: How Low Can We Go, and How Much Does Blood Pressure Matter?
Finerenone and empagliflozin together reduced proteinuria (protein in urine) by 50% compared to finenone alone. This was a small study of 32 patients over 6 months. Reducing proteinuria can slow kidney disease progression, but a study this size cannot confirm long-term benefit.
Echocardiography versus Bioimpedance in Evaluating Volume Status in Patients with Chronic Cardiorenal Syndrome: A Preliminary Study.
Echocardiography and bioimpedance (BIA) measurements of volume status were correlated in 40 patients with heart failure and kidney disease. The correlation was not strong enough to use BIA for volume status in these patients.
Interventions for the prevention of chronic kidney disease in individuals with Diabetes Mellitus and Hypertension in Africa: A scoping review protocol
This protocol reviews how to prevent kidney disease in Africa. It covers- both diabetes and hypertension, which cause most kidney failure cases.
Nephrology 2050: an evidence-informed roadmap from precision prevention to kidney regeneration.
This review covers the future of kidney health: precision prevention, AI-driven care, and regenerative medicine. It discusses how to use molecular biology to prevent kidney failure.
Real-world effectiveness of SGLT2 inhibitors in adults aged 75 years or older: a target trial emulation.
SGLT2 inhibitors may reduce kidney decline in older adults with diabetes. This study used data from Japan to compare SGLT2i with DPP4i in patients aged 75+ years. The results could change how we treat older diabetics.
AI-DMRS Model May Predict Cardiometabolic Multimorbidity and Other Multisystemic Chronic Disease Clusters in the Preclinical Stage
This study used AI to predict multi-organ disease risk in 100 patients. The model was trained on data from 5 different hospitals.
Monotypic IgA nephropathy: A large health system experience
This study of 105 patients with IgA nephropathy found that using a different-sized Biopsy needle did not affect kidney damage scores. The study lasted 3 years.
A Natural History Study of Metabolic Sizing in Health and Disease
This study will look at how metabolism differs between people with kidney disease and healthy adults. It uses a combination of-calorimetry and genetic testing.
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease
This first-in-human study will test the safety and drug levels of OJR520 in adults with kidney disease.